URGN UroGen Pharma Ltd
Price (delayed)
$13.33
Market cap
$561.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.22
Enterprise value
$438.82M
Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel,
Highlights
UroGen Pharma's equity has soared by 176% from the previous quarter and by 122% YoY
The company's EPS rose by 32% YoY and by 3.6% QoQ
The net income is down by 9% QoQ and by 4.2% YoY
Key stats
What are the main financial stats of URGN
Market
Valuations
Earnings
Shares outstanding
42.11M
Market cap
$561.38M
Enterprise value
$438.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
15.89
Price to sales (P/S)
5.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.16
Revenue
$85.01M
EBIT
-$96.34M
EBITDA
-$94.89M
Free cash flow
-$86.02M
Per share
Balance sheet
Liquidity
EPS
-$3.22
Free cash flow per share
-$2.34
Book value per share
$0.84
Revenue per share
$2.31
TBVPS
$7.65
Total assets
$281.85M
Total liabilities
$251.54M
Debt
$98.24M
Equity
$30.31M
Working capital
$244.75M
Debt to equity
3.24
Current ratio
8.15
Quick ratio
7.58
Net debt/EBITDA
1.29
Margins
Efficiency
Dividend
EBITDA margin
-111.6%
Gross margin
89.9%
Net margin
-133.6%
Operating margin
-93.7%
Return on assets
-53.2%
Return on equity
N/A
Return on invested capital
-68.4%
Return on capital employed
-38.9%
Return on sales
-113.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
URGN stock price
How has the UroGen Pharma stock price performed over time
Intraday
1.6%
1 week
-0.15%
1 month
-9.93%
1 year
-16.22%
YTD
-11.13%
QTD
-20.56%
Financial performance
How have UroGen Pharma's revenue and profit performed over time
Revenue
$85.01M
Gross profit
$76.4M
Operating income
-$79.69M
Net income
-$113.58M
Gross margin
89.9%
Net margin
-133.6%
The gross profit rose by 20% year-on-year
The revenue has grown by 17% YoY
The company's operating income fell by 15% QoQ and by 5% YoY
The operating margin is down by 14% since the previous quarter but it is up by 10% year-on-year
Growth
What is UroGen Pharma's growth rate over time
Valuation
What is UroGen Pharma stock price valuation
P/E
N/A
P/B
15.89
P/S
5.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.16
The company's EPS rose by 32% YoY and by 3.6% QoQ
UroGen Pharma's equity has soared by 176% from the previous quarter and by 122% YoY
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 4424.1 and 7% lower than the last 4 quarters average of 6.1
The revenue has grown by 17% YoY
Efficiency
How efficient is UroGen Pharma business performance
The ROA has increased by 42% YoY and by 15% from the previous quarter
URGN's return on invested capital is down by 15% since the previous quarter and by 10% year-on-year
The company's return on sales rose by 13% YoY but it fell by 10% QoQ
Dividends
What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for URGN.
Financial health
How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 12% higher than its total liabilities
UroGen Pharma's total assets has surged by 196% YoY and by 41% QoQ
The current ratio has soared by 168% year-on-year and by 9% since the previous quarter
UroGen Pharma's equity has soared by 176% from the previous quarter and by 122% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.